Restore Mind Medicine

What ISS Glossed Over Source: Company SEC Filings X MindMed's fundamentally flawed clinical development strategy. X X X MindMed management's lack of experience and expertise; Barrow, Karlin, and Liechti have never brought a drug to market. Ignoring FCM's unrefuted analysis of real-world CNS drug outcomes, while accepting Greenleaf's paid report as sufficient validation. A massive pay for performance disconnect. * FCM's good faith engagement with MindMed, including offering detailed plans to put the Company back on track. FCM resorted to director nominations after being repeatedly rebuffed. 12

View entire presentation